Drugs / Tomuzotuximab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03360734 | Nov 2017 → May 2020 | cancer | Glycotope GmbH | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tomuzotuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03360734 ↗ |
| Known as | CetuGEX | “Tomuzotuximab (CetuGEX®) is an improved second-generation anti-epidermal growth factor receptor (EGFR) antibody” NCT03360734 ↗ |
| Action | Inhibit | “acts as a competitive antagonist at the EGFR ligand binding site” NCT03360734 ↗ |
| Modality | Monoclonal antibody | “Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR” NCT03360734 ↗ |
| Target | EGFR | “Tomuzotuximab (CetuGEX®) is an improved second-generation anti-epidermal growth factor receptor (EGFR) antibody” NCT03360734 ↗ |